The International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced this week that Vivian Frittelli, Chief Executive of Generic and Biosimilar Medicines of Southern Africa (GBM), is taking over the position of IGBA Chair for 2022 from Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA).
Commenting on his new position, Frittelli – who has been involved in the pharmaceutical industry for more than 25 years – noted: “I am very pleased to take over the Chair of IGBA for the second time and look forward to building upon the strong leadership of Sudarshan Jain. Strengthened by the newly established CEO Advisory Committee, IGBA will be in a stronger position to expand its outreach relevant to its mission, priorities and operations.
“The global generic and biosimilar medicines industry,” he added, “has indeed a prominent role to play in delivering on the UN Sustainable Development Goal 3 by 2030 and in supporting pandemic mitigation initiatives for both patient care and healthcare sustainability”.
SOURCE: IGBA Communication via LinkedIn